ARDX Ardelyx Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARDX

Price (delayed)

$1.35

Market cap

$139.21M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.31

Enterprise value

$118.44M

Ardelyx is focused on discovering, developing, and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is advancing tenapanor, a novel product candidate ...

Highlights
The company's gross profit has surged by 51% YoY but it fell by 3.2% QoQ
The company's revenue rose by 49% YoY but it fell by 4% QoQ
The company's quick ratio has shrunk by 51% YoY and by 33% QoQ
The net income has decreased by 38% YoY and by 19% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ardelyx.com
Peers: OPK AMGN ABT

Key stats

What are the main financial stats of ARDX
Market
Shares outstanding
103.12M
Market cap
$139.21M
Enterprise value
$118.44M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.13
Price to sales (P/S)
10.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.54
Earnings
Revenue
$12.42M
EBIT
-$120.51M
EBITDA
-$116.41M
Free cash flow
-$117.78M
Per share
EPS
-$1.31
Free cash flow per share
-$1.18
Book value per share
$1.19
Revenue per share
$0.12
TBVPS
$2.05
Balance sheet
Total assets
$204.98M
Total liabilities
$87.41M
Debt
$65.98M
Equity
$117.57M
Working capital
$128.71M
Liquidity
Debt to equity
0.56
Current ratio
3.23
Quick ratio
2.97
Net debt/EBITDA
0.18
Margins
EBITDA margin
-937.5%
Gross margin
91.9%
Net margin
-1,009.3%
Operating margin
-979.6%
Efficiency
Return on assets
-61.5%
Return on equity
-99.1%
Return on invested capital
-88.7%
Return on capital employed
-81.9%
Return on sales
-970.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARDX stock price

How has the Ardelyx stock price performed over time
Intraday
3.05%
1 week
6.3%
1 month
-6.9%
1 year
-74.95%
YTD
-79.13%
QTD
-82.19%

Financial performance

How have Ardelyx's revenue and profit performed over time
Revenue
$12.42M
Gross profit
$11.41M
Operating income
-$121.64M
Net income
-$125.33M
Gross margin
91.9%
Net margin
-1,009.3%
The company's gross profit has surged by 51% YoY but it fell by 3.2% QoQ
The company's revenue rose by 49% YoY but it fell by 4% QoQ
The company's operating income fell by 40% YoY and by 20% QoQ
The net income has decreased by 38% YoY and by 19% from the previous quarter

Growth

What is Ardelyx's growth rate over time

Valuation

What is Ardelyx stock price valuation
P/E
N/A
P/B
1.13
P/S
10.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.54
The EPS has declined by 15% since the previous quarter and by 12% year-on-year
ARDX's P/B is 77% below its last 4 quarters average of 4.9 and 64% below its 5-year quarterly average of 3.1
Ardelyx's equity has decreased by 20% YoY and by 10% QoQ
The price to sales (P/S) is 82% lower than the last 4 quarters average of 61.5
The company's revenue rose by 49% YoY but it fell by 4% QoQ

Efficiency

How efficient is Ardelyx business performance
Ardelyx's ROE has plunged by 50% YoY and by 26% from the previous quarter
Ardelyx's ROA has decreased by 41% YoY and by 21% from the previous quarter
The return on sales has declined by 25% since the previous quarter but it has increased by 5% year-on-year
The company's return on invested capital fell by 23% YoY and by 23% QoQ

Dividends

What is ARDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARDX.

Financial health

How did Ardelyx financials performed over time
ARDX's total assets is 134% greater than its total liabilities
The company's quick ratio has shrunk by 51% YoY and by 33% QoQ
The company's current ratio fell by 49% YoY and by 34% QoQ
Ardelyx's debt is 44% lower than its equity
Ardelyx's debt to equity has surged by 51% YoY and by 40% QoQ
Ardelyx's debt has increased by 25% QoQ and by 22% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.